On this page
Biotin-thiamine-responsive basal ganglia disease
This condition primarily affects children and young adults, causing neurological symptoms that can include movement problems and developmental regression. It is characterised by a specific response to biotin and thiamine supplementation.
Available at Jeen Health
Clinical tests that include this
Overview
Biotin-thiamine-responsive basal ganglia disease (BTBGD) is a rare inherited condition that affects the brain, particularly a deep brain region called the basal ganglia. This part of the brain is crucial for controlling movement, learning, and emotions. The condition typically manifests in childhood or early adulthood, although onset can vary [PMID:24075138]. Symptoms can appear suddenly, often following a fever, and may worsen over time if untreated. However, many individuals respond well to vitamin supplements, specifically biotin and thiamine.
Symptoms & clinical features
Individuals with BTBGD commonly experience neurological symptoms, which can include difficulty with movement, such as dystonia (involuntary muscle contractions causing twisting or repetitive movements) or spasticity (muscle stiffness) [PMID:24075138]. Other features may involve speech difficulties (dysarthria), problems with coordination (ataxia), and intellectual regression. Some affected individuals may also have seizures or exhibit psychiatric symptoms. The severity of these symptoms can vary significantly between individuals and may fluctuate, especially if treatment is inconsistent.
Video: Genetics 101
Affected organs
The primary organ affected by biotin-thiamine-responsive basal ganglia disease is the brain. In particular, the basal ganglia, located deep within the brain, are typically impacted. Imaging studies, such as MRI scans, often show abnormalities in this region. This damage to the basal ganglia underlies the characteristic movement disorders and neurological symptoms seen in individuals with the condition.
Risks & severity
BTBGD is a progressive disorder, meaning symptoms can worsen over time if not managed. However, the severity of the condition is highly variable. If left untreated, it can lead to severe neurological impairment, including significant motor and cognitive decline. Early diagnosis and consistent treatment with biotin and thiamine are crucial, as they can often lead to substantial clinical improvement and, in some cases, a near-complete recovery, particularly if treatment begins before significant permanent brain damage occurs [PMID:24075138]. The exact prevalence of BTBGD is not well established due to its rarity.
Genetic causes
Biotin-thiamine-responsive basal ganglia disease is caused by pathogenic variants in the SLC19A3 gene. This gene provides instructions for making a protein that transports thiamine (vitamin B1) into cells. Thiamine is essential for several metabolic processes, particularly in the brain, where it helps convert food into energy. When the SLC19A3 gene has a pathogenic variant, it can lead to a deficiency of thiamine in the brain cells, even if there is enough thiamine in the diet. This cellular thiamine deficiency disrupts energy production and brain function, leading to the symptoms observed in BTBGD [PMID:22081514].
- SLC19A3 solute carrier family 19 member 3The SLC19A3 gene provides instructions for a thiamine transporter protein, vital for moving vitamin B1 into cells, especially those of the nervous system.
Inheritance pattern
Biotin-thiamine-responsive basal ganglia disease is inherited in an autosomal recessive pattern. This means that an individual must inherit two copies of the altered SLC19A3 gene - one from each parent - to develop the condition. People who have only one copy of an altered gene are called carriers; they typically do not show symptoms of the disorder but can pass the altered gene on to their children. If both parents are carriers of a pathogenic SLC19A3 variant, there is a 25% chance with each pregnancy that their child will inherit two altered copies and develop BTBGD, a 50% chance the child will be a carrier, and a 25% chance the child will not inherit any altered copies.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of BTBGD is primarily based on clinical symptoms and brain imaging findings, typically an MRI scan showing characteristic changes in the basal ganglia. However, confirmation requires genetic testing, which identifies pathogenic variants in the SLC19A3 gene. In the UK, genetic testing for this condition would typically be initiated by a clinical geneticist or a neurologist, following an NHS Genomic Medicine Service (GMS) pathway. The relevant NHS R-code for testing for inherited metabolic disorders, which includes BTBGD, may be used for such referrals. Genetic counselling is an important part of the diagnostic process, offering support and information to families awaiting results.
Management & lifestyle
The management of BTBGD centres on supplementation with high doses of biotin and thiamine. This treatment is often remarkably effective, particularly if started early in the disease course. Dosage and specific formulation of these vitamins are guided by specialist clinicians. Regular follow-up appointments with a neurologist and other specialists are important to monitor the individual's response to treatment and to manage any persistent symptoms. This may include physiotherapy for movement difficulties or educational support for developmental challenges. Adherence to the treatment regimen is crucial for optimising outcomes.
UK care pathway
In the UK, if BTBGD is suspected, a referral to a clinical genetics service or specialist neurology centre via the NHS Genomic Medicine Service is the typical pathway. Genetic testing for SLC19A3 variants would be requested, often using an appropriate R-code for inherited neurological or metabolic conditions. A genetic counsellor will provide support and information throughout this process, helping families understand the genetic basis of the condition, inheritance patterns, and implications for other family members.
Frequently asked questions
Is biotin-thiamine-responsive basal ganglia disease treatable?
Yes, BTBGD is generally considered treatable with high doses of biotin and thiamine supplements. Early and consistent treatment can lead to significant improvement in symptoms and can even prevent further neurological damage in some cases.
What happens if BTBGD is left untreated?
If BTBGD is left untreated, symptoms typically worsen over time, leading to progressive neurological decline. This can result in severe movement problems, intellectual disability, and a lower quality of life.
Are my siblings or children at risk if I have BTBGD?
Since BTBGD is an autosomal recessive condition, your siblings may be carriers or affected if your parents are also carriers. For your children, if you have BTBGD, they would inherit one altered gene copy from you. Whether they also develop the condition would depend on whether they inherit another altered copy from your partner. Genetic counselling can provide personalised risk assessments.
How common is biotin-thiamine-responsive basal ganglia disease?
Biotin-thiamine-responsive basal ganglia disease is a very rare condition. Its exact prevalence is not precisely known, but it is considered to be one of the less common inherited metabolic disorders.
What kind of doctor manages this condition?
Management of BTBGD is typically overseen by a neurologist, often in conjunction with a clinical geneticist or a metabolic specialist. A team of healthcare professionals, including physiotherapists and speech therapists, may also be involved in providing comprehensive care.
References
- Karachaliou CE, Livaniou E. Biotin Homeostasis and Human Disorders: Recent Findings and Perspectives. International journal of molecular sciences. 2024. PMID: 38928282
- Adam MP, Bick S, Mirzaa GM. Biotin-Thiamine-Responsive Basal Ganglia Disease. 1993. PMID: 24260777
- Saini AG, Sharma S. Biotin-Thiamine-Responsive Basal Ganglia Disease in Children: A Treatable Neurometabolic Disorder. Annals of Indian Academy of Neurology. 2021. PMID: 34220059
- Sondhi V, Sharma S. Vitamin-Responsive Movement Disorders in Children. Annals of Indian Academy of Neurology. 2020. PMID: 32606520
- Algahtani H, Ghamdi S, Shirah B. Biotin-thiamine-responsive basal ganglia disease: catastrophic consequences of delay in diagnosis and treatment. Neurological research. 2017. PMID: 27905264
- Majumdar S, Salamon N. Biotin-thiamine-responsive basal ganglia disease: A case report. Radiology case reports. 2022. PMID: 35003475
- Alabdulqader MA, Al Hajjaj S. Biotin-Thiamine-Responsive Basal Ganglia Disease: Case Report and Follow-Up of a Patient With Poor Compliance. Child neurology open. 2018. PMID: 29770345
- Aburezq M, Alahmad A, Alsafi R. Biotin-thiamine responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of cases in Kuwait with novel variants. Orphanet journal of rare diseases. 2023. PMID: 37670342